Difference between revisions of "BL22 immunotoxin (CAT-3888)"

Latest revision as of 14:33, 28 February 2024

No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.

General information

Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.

The original manufacturer was acquired in 2005.^[1] Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic Moxetumomab pasudotox (HA22).

Preliminary data

Hairy cell leukemia

Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. link to original article PubMed
Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. link to original article link to PMC article PubMed

Also known as

Code names: CAT-3888, GCR-3888

References

↑ Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.

[1] Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.

[1]

@@ Line 1: / Line 1: @@
-'''In clinical trials.'''  Also known as GCR-3888.  Related to GCR-8015/CAT-8015, which have increased affinity to CD22.
+'''No longer in clinical development. Related to GCR-8015/CAT-8015, which have increased affinity to CD22.'''
 ==General information==
-Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38.  BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC  (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref><ref>R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=3999 Long term follow-up of BL22 in cladribine-resistant hairy cell leukemia.] 2004 ASCO Annual Meeting abstract 6624.</ref><ref>R. J. Kreitman, W. H. Wilson, M. Stetler-Stevenson, P. Noel, D. J. FitzGerald, I. Pastan. [http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34304 Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia.] 2007 ASCO Annual Meeting abstract 7095.</ref>
+Class/mechanism: Recombinant anti-CD22 immunotoxin fusion protein comprised of a murine anti-CD22 antibody fragment (disulphide-linked Fv, dsFv) and Pseudomonas exotoxin PE38. BL22 binds to CD22 positive cells and is endocytosed, resulting in intracellular release of the toxin and cell death.
-<br>Route: IV
-<br>Extravasation: no information
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
+The original manufacturer was acquired in 2005.<ref>[http://www.biospace.com/news_print.aspx?NewsEntityId=1132 Cambridge Antibody Technology Group PLC (CATG) Acquires Oncology Product Candidates From Genencor International, Inc.]</ref> Development of this drug was discontinued in 2008, at which time it was superseded by the more potent and less toxic [[Moxetumomab pasudotox (HA22)]].
-==Clinical trials==
+==Preliminary data==
-*[http://clinicaltrials.gov/ct2/show/NCT00923013 Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia]
+===[[Hairy cell leukemia]]===
-*[http://clinicaltrials.gov/ct2/show/NCT00924040 Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia]
+# Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241-7. [https://doi.org/10.1056/NEJM200107263450402 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11474661/ PubMed]
-*[http://clinicaltrials.gov/ct2/show/NCT00074048 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia]
+# Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. [https://doi.org/10.1200/jco.2008.20.2630 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc2702232/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19414673/ PubMed]
-==Patient drug information==
+==Also known as==
-No information available.
+*'''Code names:''' CAT-3888, GCR-3888
 ==References==
 <references/>
+[[Category:Drugs]]
+[[Category:Intravenous medications]]
+[[Category:Immunotoxin]]
+[[Category:Anti-CD22 immunotoxins]]
+[[Category:Recombinant medications]]
+[[Category:Halted drugs]]